Keynote 024 5 Year Update 2024

Keynote 024 5 Year Update 2024. Professor reck explains that there was an opportunity for patients who experienced disease progression after benefitting from pembrolizumab to receive a second course of. Eligible pts were randomized to pembro (200 mg q3w for up to 35 cycles [∼2 years]) or chemo.

Clinical trial updates provide an opportunity to disseminate additional results from studies, published in jco or elsewhere, for which the primary end point has already been reported. Eligible pts were randomized to pembro (200 mg q3w for up to 35 cycles [∼2 years]) or chemo.